We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA hit Chinese firm Zhejiang Ludao Technology with a warning letter after an August inspection revealed significant testing issues at its Taizhou, Zhejiang facility. Read More
CBER’s advertising and promotional labeling branch sent an untitled letter to a drugmaker in Pennsylvania saying the company overpromised the impact of its hemophilia treatment. Read More
Opioid sales increased more than eightfold between 1992 and 2015, according to a new analysis by the FDA that found no clear links between price and volume. Read More
The Drug Enforcement Administration told an Ohio federal judge it would divulge nearly a decade’s worth of data on opioid sales after long resisting the disclosure, but only under a “for attorneys’ eyes only” protective order. Read More